$74.70-5.01% · 3M
Moving avg
1W-2.68%
1M-9.58%
3M-1.51%
6M+12.74%
YTD+21.01%
1Y+92.93%
3Y+132.71%
5Y+139.73%
52-week range
$32.8975% of range$88.31
Company health
Value0/6
Growth1/6
Profitability2/6
Health4/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 47% upside to a $110 target
- Analyst consensus is "Buy"
- High return on equity (13966%)
Risks
- Currently unprofitable
- Burning free cash flow
Key statistics
Valuation
Market cap
$9.30B
Enterprise value
$11.35B
P/E ratio (TTM)
-11.99x
P/S ratio (TTM)
96.33x
EV/EBITDA
-15.45x
Per share & returns
EPS (TTM)
-$6.73
Dividend yield
0.00%
Beta (1Y)
0.42
30-day change
-9.58%
Trading
Volume (24h)
592.59K
Previous close
$75.64
Shares outstanding
124.43M
About Cytokinetics, Incorporated
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
CYTK
Cytokinetics, Incorporated is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker CYTK.
Frequently asked questions
What is Cytokinetics, Incorporated's market cap?
Cytokinetics, Incorporated (CYTK) has a market capitalization of $9.30B.
What sector is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated operates in the Healthcare sector, Biotechnology industry.
What exchange does CYTK trade on?
CYTK trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,216.03-0.35%
$1.15T cap
Johnson & JohnsonJNJ
$261.33+0.18%
$629.78B cap
AbbVie Inc.ABBV
$250.78+0.81%
$443.08B cap
UnitedHealth Group IncorporatedUNH
$402.12-0.86%
$365.18B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$354.73B cap
Merck & Co., Inc.MRK
$134.53+1.21%
$332.26B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.30B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.01B cap